Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 2c; Offers FY23 Revenue Guidance
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $24.28 -1.18%
EPS Growth %: -266.7%
Financial Fact:
Operating loss: -32.21M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -266.7%
Financial Fact:
Operating loss: -32.21M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $44.87 million.
GUIDANCE:
Adaptive Biotechnologies sees FY2023 revenue of $205-215 million, versus the consensus of $207.2 million.
For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
